Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05815342 · ClinicalTrials.gov registry record · NA

OP5-005 Using Omnipod 5 in Adults With Type 2

A NA study, sponsored by Insulet Corporation.

Completed
Registry status
NA
Development phase
343
Enrollment target

NCT05815342: Completed NA study, sponsored by Insulet Corporation.

NCT05815342 is a NA study that has completed, run by Insulet Corporation. The registered enrollment target is 343 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (76% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05815342, a NA study, has completed, sponsored by Insulet Corporation.

COMPLETED
Registry status
NA
Development phase
343 participants
Enrollment target

Study Summary

This is a single arm, multi-center, prospective study that will evaluate the safety and efficacy of the Omnipod 5 Automated Insulin Delivery System in adults with type 2 diabetes requiring insulin therapy.

Primary Outcome

The change in HbA1c at 13 weeks from baseline

Interventions

  • DEVICE Omnipod 5 Automated Glucose Control System

Trial Details

FieldValue
Enrollment Target 343 participants
Start Date 2023-04-11
Est. Completion 2024-03-01
Phase NA
Insulet Corporation

16 total trials

What the finished NCT05815342 record still lists

NCT05815342 is an interventional study that assigns participants to a tested intervention. The registered 343 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (76% lower).

The record links to 0 conditions, and to 1 intervention - of which Omnipod 5 Automated Glucose Control System is the first listed.

NCT05815342 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT05815342 about?

NCT05815342 is a clinical study titled "OP5-005 Using Omnipod 5 in Adults With Type 2". This is a single arm, multi-center, prospective study that will evaluate the safety and efficacy of the Omnipod 5 Automated Insulin Delivery System in adults with type 2 diabetes requiring insulin therapy.

What is the current status of trial NCT05815342?

This trial is currently completed. It is a NA study. The enrollment target is 343 participants. The study started on 2023-04-11. Estimated completion is 2024-03-01.

What interventions are being tested in trial NCT05815342?

The interventions under investigation include: Omnipod 5 Automated Glucose Control System (DEVICE).

Who is sponsoring clinical trial NCT05815342?

This trial is sponsored by Insulet Corporation, which has 16 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT05815342's enrollment target sits among peer trials

343 302nd of 2000 higher than 1,699 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT06733363 · 344 participants · Phase 2

    A Cruciferous Vegetable Eating Program for the Reduction of Cancer Recurrence and Progression in Patients With Non-muscle Invasive Bladder Cancer

  • NCT07179380 · 344 participants · Phase 3

    Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

  • NCT07304024 · 344 participants · Phase 1

    A Treatment for a Form of Age-Related Central Auditory Processing Disorder Consisting of Clemastine Fumarate Plus Engineered Sound

  • NCT05283850 · 342 participants · Phase 2

    Surviving PEA in Roanoke (SPEAR) Study

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05815342, the US trial registry maintained by the National Library of Medicine. NCT05815342 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.